

Supplementary Information

Riccardo Porta, Maurizio Benaglia *, Francesca Coccia, Sergio Rossi and Alessandra Puglisi *

1. General Configuration of Continuous Flow Apparatus





Figure S1. General configuration of continuous flow apparatus.

2. Synthesis of (*S*)-Warfarin

2.1. General Procedure for Batch Reaction




Into a vial, catalyst **10** (5 mg, 0.015 mmol) was suspended in dry dioxane (1.5 mL) under nitrogen atmosphere then trifluoroacetic acid (0.03 mmol), benzalacetone (0.3 mmol) and 4-hydroxycoumarin (0.15 mmol) were added; the vial was sealed and the mixture was stirred at 30 °C for 24 h. The mixture was then diluted with AcOEt (3 mL) and HCl solution (10 wt%, 1 mL) was added. The organic phase was separated and the aqueous layer was extracted twice with AcOEt (4 mL). The combined organic layer were concentrated and the crude mixture was injected to HPLC in order to determine the enantiomeric excess.

Table S1. Screening of solvents for the stereoselective synthesis of (*S*)-Warfarin.


Entry	Solvent	ee (%)
1	CH ₂ Cl ₂	80
2	THF	84
3	Toluene	77
4	CHCl ₃	82
5	DME	87
6	Dioxane	95

ACAC+NITROSTYRENE/1
F300 CDCl₃




(a)

Figure S2. *Cont.*



(b)



(c)

Figure S2. ¹H-NMR spectra.




Figure S3. HPLC traces. Chiralcel OD-H column, eluent Hexane/EtOH = 95/5, flow rate 0.8 mL/min, $\lambda = 210$ nm




Figure S4. HPLC traces. Chiralcel OD-H column, eluent Hexane/*i*PrOH = 98/2, flow rate 0.8 mL/min, $\lambda = 210$ nm.




Figure S5. HPLC traces. Chiralcel AD column, eluent Hexane/*i*PrOH = 8/2 + 0.1% TFA, flow rate 0.8 mL/min, λ = 280 nm.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).